Asthmatic reaction induced by Etoricoxib in a patient with aspirin-sensitive asthma
First published: 08 July 2008
No abstract is available for this article.
References
- 1
Szcezeklik E,
Nizankowska E,
Bochenek G,
Nagraba K,
Mejza F,
Swierczynska M.
Safety of a specific COX-2 inhibitor in aspirin-induced asthma.
Clin Exp Allergy
2001; 31: 219–225.
- 2
Stevenson DD,
Simon RA.
Lack of cross-reactivity between Rofecoxib and aspirin in aspirin-sensitive patients with asthma.
J Allergy Clin Immunol
2001; 108: 47–51.
- 3
Woessner KM,
Simon RA,
Stevenson DD.
The safety of Celecoxib in patients with aspirin-sensitive asthma.
Arthritis Rheum
2002; 46: 2201–2206.
- 4
Sanches-Borges M,
Caballero-Fonseca F,
Capriles-Hulett A.
Safety of Etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
Ann Allergy Asthma Immunol
2005; 95: 154–158.
- 5
Viola M,
Quaratino D,
Gaeta C,
Caruso C,
Valluzzi R,
Romano A.
Etoricoxib tolearbility in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs.
Int Arch Allergy Immunol
2007; 143: 103–108.
- 6
Nahar IK,
Muqim AT,
Al-Qhouti BI,
Al-Herz AA,
Shehab DK,
Uppal SS
et al.
The use of Etoricoxib in patients with bronchial asthma associated with aspirin sensitivity.
Saudi Med J
2006; 27: 119–120.
